00:04 , Mar 9, 2019 |  BC Extra  |  Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

Neurology company Lundbeck hired Keld Flintholm Jørgensen as its first CBO. Jørgensen, who will begin at H. Lundbeck A/S (CSE:LUN) April 4, is global head of strategic partnering at Roche (SWX:ROG;OTCQB:RHHBY). Innovative Cellular Therapeutics Co....
02:33 , Dec 8, 2018 |  BioCentury  |  Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
00:04 , Sep 22, 2017 |  BC Extra  |  Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
07:00 , Jun 25, 2015 |  BC Innovations  |  Product R&D

Cellectis' UCART-ography

A year after Pfizer Inc. threw its weight behind Cellectis S.A. 's chimeric antigen receptor (CAR) T cell platform, the biotech has signed a three-year partnership with Weill Cornell Medical College to test whether its...
07:00 , Jun 11, 2015 |  BC Innovations  |  Product R&D

All four one

Amphivena Therapeutics Inc. licensed Affimed N.V. 's tetravalent antibody-mimetic technology two years ago to create blood cancer therapeutics that would be simpler to use and safer than CAR T cell therapies. Now, the start-up has...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Affimed, J&J deal

Affimed's Amphivena Therapeutics Inc. subsidiary in the U.S. granted Johnson & Johnson's Janssen Biotech Inc. subsidiary an exclusive option to acquire Amphivena following an IND approval by FDA or major EU agencies. Prior to Janssen's...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Affimed board of directors update

Affimed Therapeutics AG , Heidelberg, Germany   Business: Cancer, Inflammation, Antibodies   Appointed: Luke Evnin, managing director of MPM Capital, as a director of Affimed's Amphivena Therapeutics Inc. subsidiary; Phil Gutry, principal at MPM Capital,...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Financial News

Affimed completes venture financing

Affimed Therapeutics AG , Heidelberg, Germany   Business: Cancer, Inflammation, Antibodies   Date completed: 7/15/13   Type: Venture financing   Raised: $14 million   Investors: MPM Capital; Aeris Capital; Affimed Therapeutics AG   Note: Affimed's...